Receive alerts
Market Cap:
$106.63 m
0.40 USD
52 weeks high
52 weeks low

BioPorto Diagnostics have through dedicated research and product development been able to offer a strong range of thoroughly validated antibodies, which can be used for pharmaceutical as well as scientific research. We offer several antibodies with high specificity within medical specialties such as Obesity, Diabetes and Primary Immune Deficiency. For research use only.


The NGAL Test – first diagnostic acute kidney injury biomarker which can be measured in both human urine and plasma.

Acute kidney injury (AKI), previously known as acute renal failure, represents a medical emergency and encompasses a wide range of injury to the kidneys. Acute kidney injury is a rapid deterioration of renal function, resulting in an inability to maintain fluid, electrolyte and acid-base balance. AKI increase morbidity and mortality and due to the severity of acute kidney injury the healthcare costs are significant. As a result of this increased efforts into identifying new acute kidney injury biomarkers can be seen, as biomarkers addressing the need for earlier diagnosis of AKI would ultimately save lives, raise quality of life for patients worldwide and save costs for the healthcare system.

BioPorto Diagnostics offers a wide range of monoclonal antibodies, provided with detailed information. When looking at our antibodies, you are provided with detailed specification such as species reactivity, epitope specificity, storage information, etc.

Bulk antibodies supplied from BioPorto
We have in-house scale up capabilities for production and delivery of antibodies in bulk volumes, in order to meet your needs. Bulk order production will be backed up by our stringent quality control system, which is ISO certified, and which will ensure that your requirements in quality and batch-to-batch consistency are secured. We are happy to work together with you and will offer you bulk effective pricing, hereby presenting the best solution for you

BioPorto Diagnostics offers a range of market leading and ready-to-use ELISA Kits. The kits are highly reproducible and easy-to-use.

When looking at our ELISA Kits, you are provided with the detailed product specification such as target information, assay range, species reactivity, storage information, etc.

Our NGAL ELISA (Human) Kit 036 and our MBL Oligomer ELISA Kit 029 are CE-marked, but are not available in the USA for in vitro diagnostic use.

BioPorto Diagnostics offers antigens such as the only commercially available human monoclonal IgE.

This human IgE is used widely in the field of allergy research and diagnostic kit manufacturing, mostly as a standard in quantitatíve IgE assays and for internal control and QC purposes.

For more information, please click here

Denmark & US


Peter Mørch Eriksen was appointed CEO of BioPorto in July 2013. Peter Mørch Eriksen has more than 15 years of experience within medtech/life science in Denmark and abroad. Prior to joining BioPorto, Peter Mørch Eriksen was CEO of Sense A/S and before this, he held positions as Vice President of Medtronic in both the USA and Denmark. From these positions Peter Mørch Eriksen brings extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. Peter Mørch Eriksen has an accounting background supplemented with courses in management. In addition to being CEO of BioPorto, Peter Mørch Eriksen chairs the board of MTIC, is a board member at Nervex A/S, member of Lund University Advisory Board, and Director of PMEconsult ApS. He also serves on the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US.


Ole Larsen was appointed CFO of BioPorto in June 2018. Ole Larsen brings comprehensive industrial and financial knowledge to BioPorto as an experienced executive in international health care and media companies. Most recently from Bavarian Nordic A/S, a NASDAQ-listed Danish biotechnology company focused on cancer immunotherapies and vaccines for infectious diseases. Since 2008, Ole Larsen served as Executive Vice President and CFO and was responsible for Finance, IR and IT. Prior to this, Ole Larsen held CFO positions at two of the largest Danish and Nordic media groups, Nordisk Film and Berlingske Tidende. Ole Larsen holds a MSc in Economics from Copenhagen Business School.


Jan Kuhlmann Andersen was appointed COO of BioPorto in August 2016. Jan Kuhlmann Andersen is a very experienced executive having worked with sales within the life sciences area, mostly in US-owned companies such as FMC, Cambrex, Fisher Scientific and Thermo Fisher Scientific since 1995. From 2007 and until joining BioPorto, Jan Kuhlmann Andersen was Vice President, sales & marketing, in the Animal Health & Nutrition division in Chr. Hansen A/S. Jan Kuhlmann Andersen holds a PhD in immunology and a MSc in Biology, both from the University of Copenhagen. Jan Kuhlmann Andersen also serves as the Chairman of Cytovac A/S and was previously board member of Noscomed Medical Supply A/S, the French life science company Cell Made and of BioPorto A/S from 2015 to 2016.


MBA from INSEAD and PhD and MSc from the Technical University of Denmark

Chairman and Board member since 2013

Thomas Magnussen is Chairman and co-founder and partner in QuantumWise A/S and Zylinc A/S respectively as well as an entrepreneur in the high-tech space, engaging in start-up companies with global business scope. Thomas Magnussen has experience in commercialization strategies and from industries including nanotechnology, ICT and medtech.


DIEUs top management education, VL and banking education

Board member since 2013

Torben A. Nielsen has for more than 25 years held senior positions in the financial sector. From 1998 to 2008 he was member of the executive management in Sydbank A/S responsible for asset management, capital markets, treasury, foreign and several other business areas, and from 2008 to 2012 he was the CEO of BankInvest A/S. Concurrently, he has held several national and international board positions, including at NASDAQ OMX. Of a total of 30 years in the financial sector, of which 5 years in New York and London, Torben A. Nielsen built and managed businesses at home and abroad in all relevant commercial business areas in the financial sector and has been involved in and responsible for several mergers and acquisitions.


MSc and PhD in pharmacology from the University of Copenhagen.

Board member since 2017.

Kirsten Aarup Drejer is co-founder of Symphogen A/S, a biopharmaceutical company focused on the innovative therapeutic utilization of antibodies. In the period from 2000 until 2016, Kirsten Aarup Drejer was CEO of Symphogen A/S. Before this, Kirsten Aarup Drejer held a number of scientific and managerial positions within Novo Nordisk A/S. Kirsten Aarup Drejer is a member of the board of directors of Symphogen A/S and the Danish Growth Fund and has previously been a member of the board of directors of, among others, Danisco A/S. Kirsten Aarup Drejer is a member of numerous advisory boards at the University of Copenhagen and the Copenhagen Business School. Kirsten Aarup Drejer won the prize of ”BiotechBuilder of the Year” in 2003 and ”Entrepreneur of the Year, Biotech” in 2007

BioPorto Diagnostics, Inc
444 N. Michigan Avenue, Suite 3350
Chicago, IL 60611

E-MAIL: info@bioporto.com